Ophthalmology

Thomas discusses emerging therapies, new technologies, and the reform needed to help these new developments reach the patients in need of them.

Landela’s research on an impoverished community in South Africa encourages clinicians to help similar populations get the care they need.

Veeral Sheth, MD, is joined by the director of marketing of eSight to discuss the 5th generation eSight Go, a device to enhance central vision functions in patients with a variety of eye diseases.

A review of the 16 novel drugs approved by the US Food and Drug Administration during the first half of 2025, with links to coverage from MJH Life Sciences publications.

Our recap of the first half of 2025 highlights 5 regulatory updates, 5 trial announcements, and 3 top perspectives in eyecare.

Our Q2 2025 recap for ophthalmology highlights 5 regulatory updates, 5 important trial announcements, and top perspectives in eyecare.

June was characterized by HCPLive’s coverage of the AOA 2025 Conference in Minneapolis and a host of cross-specialty disease indicators and drug uses.

A worldwide increase in both near-work and screen usage has led to a spike in myopia rates; this study associates this with near exophoria caused by close reading.

A recent post hoc analysis of 2 pivotal phase 3 trials has determined the efficacy of acoltremon .003% in reducing ocular surface damage in dry eye disease.

Based on recent data, artificial intelligence can improve patients’ awareness of their condition, as well as confidence in, and satisfaction with, their care.

Research has indicated a substantial increase in axial length, a contributing factor of myopia, in young adults who report regular mobile device usage.

Despite its availability as an over-the-counter medication, BTOS is frequently prescribed by clinicians for the treatment of ocular redness due to minor eye irritations.

This interim report of an ongoing study has indicated an overall positive impression of the INFUSE for Astigmatism contact lens among a 100-patient population.

A survey study has indicated a substantially positive perspective on UMFfA contact lenses, including reports on well-maintained vision, comfort, and ease of fitting.

Lifitegrast 5% led to improvements in OSDI, MMP-9, tear osmolarity, and a variety of other biomarkers and clinical signs of DED.

New research has associated complement factors from both the classical and terminal pathways with progression from intermediate to advanced age-related macular degeneration.

Despite the possibility for enhanced stability of IOL rotation and tilt, the potential for ACD increase and a resulting hyperopic refractive shift warrants caution.

The company believes results from a recent phase 3 chamber trial fulfill the FDA’s requests in the Complete Response Letter received in April of 2025.

Pseudoexfoliation results in the ganglion cell layer degradation that precedes glaucoma, indicating a potential predictor.

An audio recap of the top 5 stories in healthcare news from the week of 06/02-06/08.

Parent company Amneal Pharmaceuticals, Inc. has announced intentions to launch the topical anti-inflammatory agent in the third quarter of 2025.

GLP-1 RAs, one of the most common medications for obesity and diabetes, have several inherent risks that are often overlooked in favor of their efficacy.

This recent study highlights the intricate variations between glaucoma cases, encouraging a more individual approach to analyzing treatment responses.

If approved, lamivudine may bring DME treatment and better vision outcomes to communities who cannot afford more costly intravitreal injections.

This May was characterized by HCPLive’s coverage of the ARVO and Envision conferences, as well as a slew of FDA approvals towards the end of the month.